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Abstract
Objective: To determine the frequency of distinctive EGFr cysteine altering
NOTCH3 mutations in the 60,706 exomes of the exome aggregation consor-
tium (ExAC) database. Methods: ExAC was queried for mutations distinctive
for cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy (CADASIL), namely mutations leading to a cysteine
amino acid change in one of the 34 EGFr domains of NOTCH3. The genotype-
phenotype correlation predicted by the ExAC data was tested in an independent
cohort of Dutch CADASIL patients using quantified MRI lesions. The Dutch
CADASIL registry was probed for paucisymptomatic individuals older than
70 years. Results: We identified 206 EGFr cysteine altering NOTCH3 mutations
in ExAC, with a total prevalence of 3.4/1000. More than half of the distinct
mutations have been previously reported in CADASIL patients. Despite the
clear overlap, the mutation distribution in ExAC differs from that in reported
CADASIL patients, as mutations in ExAC are predominantly located outside of
EGFr domains 1–6. In an independent Dutch CADASIL cohort, we found that
patients with a mutation in EGFr domains 7–34 have a significantly lower MRI
lesion load than patients with a mutation in EGFr domains 1–6. Interpretation:
The frequency of EGFr cysteine altering NOTCH3 mutations is 100-fold higher
than expected based on estimates of CADASIL prevalence. This challenges the
current CADASIL disease paradigm, and suggests that certain mutations may
more frequently cause a much milder phenotype, which may even go clinically
unrecognized. Our data suggest that individuals with a mutation located in
EGFr domains 1–6 are predisposed to the more severe “classical” CADASIL
phenotype, whereas individuals with a mutation outside of EGFr domains 1–6
can remain paucisymptomatic well into their eighth decade.
Introduction
Cerebral autosomal dominant arteriopathy with subcorti-
cal infarcts and leukoencephalopathy (CADASIL) is a
monogenic small vessel disease caused by highly distinc-
tive mutations in the NOTCH3 gene.1 NOTCH3 muta-
tions in CADASIL lead to (cerebro)vascular NOTCH3
protein aggregation, compromised cerebral blood flow,
mid-adult onset of stroke and vascular cognitive impair-
ment, and migraine with aura. Although most patients
experience their first stroke at 45–50 years of age, there is
a wide variability in age of onset and disease progression,2
and a later-onset, milder disease course is increasingly
recognized.3
CADASIL patients have progressive ischemic brain
MRI abnormalities, which correlate with disease
severity.4–6 In the presymptomatic stage of the disease, up
to decades before onset of symptoms, symmetric peri-
ventricular white matter hyperintensities (WMH) are
observed,7,8 often also affecting the anterior temporal
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lobes. The MRI in symptomatic individuals often also
reveals multiple lacunar infarcts, microbleeds, and brain
atrophy.9,10
CADASIL has been reported worldwide, but only some
countries in Europe and East Asia have compiled large
series of CADASIL patients and their NOTCH3 muta-
tions.11–17 Prevalence studies have been performed in rela-
tively small populations, with a reported minimum
prevalence of 2-5/100,000.3,18,19 This number is widely
held to be an underestimation.3
Over 98% of CADASIL patients have a distinctive mis-
sense mutation in one of NOTCH3 exons 2–24, invariably
leading to the gain or loss of a cysteine residue in one of
the 34 epidermal growth factor-like repeat (EGFr)
domains of the NOTCH3 protein. This changes the highly
conserved number of six cysteines in one of these EGFr
domains to an uneven number of five or seven cys-
teines.12 The resultant unpaired cysteine is predicted to
lead to abnormal disulphide bridge formation and
NOTCH3 protein aggregation.20 More than 200 distinct
NOTCH3 mutations have been identified in CADASIL
patients, dispersed across EGFr domains 1–34, but with
the highest prevalence in EGFr domains 1–6.21 Nonpene-
trance has never been reported for this distinct type of
NOTCH3 mutation. A definite, clinically relevant geno-
type-phenotype correlation has never been found.13,14
In this study, we determined the prevalence of EGFr
cysteine altering NOTCH3 mutations in the large publi-
cally accessible exome sequencing dataset ExAC and per-
formed comparative analyses with the over 200 NOTCH3
mutations reported in both the Dutch and international
CADASIL population. The genotype-phenotype associa-
tion predicted by comparing ExAC and CADASIL muta-
tion spectra was assessed in an independent cohort of
Dutch CADASIL patients. We discuss the implications of
our findings for the prevalence of CADASIL, the ever-
broadening disease spectrum, and the discovery of a novel
genotype-phenotype correlation.
Materials and Methods
The Exome Aggregation Consortium dataset
NOTCH3 mutation frequencies were assessed using the
browser of the Exome Aggregation Consortium (ExAC)
(Lek et al.; http://dx.doi.org/10.1101/030338; http://
exac.broadinstitute.org; accessed Oct/Nov 2015). This
publically accessible database contains exome data of
60,706 unrelated individuals; 33,644 males and 27,062
females. The exome data are compiled from 14 indepen-
dent disease and control cohorts. No specific stroke or
dementia cohorts are included in ExAC. Individuals in
ExAC are assigned to one of six populations: European
(n = 36,677; Finnish n = 3307, Non-Finnish n = 33,370),
Latino (n = 5789), African/African American (n = 5203),
South Asian (n = 8256), East Asian (n = 4327), and
Other (n = 454). Data in ExAC are based on genome
build GRCh37/hg19.
NOTCH3 variant ascertainment in ExAC
We queried ExAC for missense mutations in NOTCH3
that passed all ExAC quality checks (Lek et al.; http://dx.-
doi.org/10.1101/030338). Next, these variants were filtered
using stringent criteria for pathogenicity in CADASIL,
namely missense mutations leading to the gain or the loss
of a cysteine residue in one of the 34 EGFr domains of
the NOTCH3 protein (amino acid residues 40–1373)
(http://www.uniprot.org). Mean coverage of the NOTCH3
canonical transcript in ExAC is 35.729. Most of the EGFr
encoding exons (exons 2–24) have a coverage of at least
109, except for exon 15 and a part of exon 24, which
have a coverage below 10x. Four independently accessible
cohorts contributing to the ExAC database were also indi-
vidually queried for pathogenic NOTCH3 mutations:
1000 Genomes (http://www.1000genomes.org); NHLBI-
GO Exome Sequencing Project (http://evs.gs.washington.
edu); Sequencing Initiative Suomi (http://www.sisu
project.fi/) and Type 2 DiabetesGenetics 17k exome
sequence analysis (http://www.type2diabetesgenetics.org).
Comparison of NOTCH3 mutations in ExAC
to those reported in CADASIL patients
NOTCH3 mutations present in ExAC were compared to
those reported in the Dutch CADASIL registry and the
international CADASIL literature. To avoid bias through
incomplete reporting of mutation frequencies or founder
effects, the comparative analysis of the mutation distribu-
tion across the 34 EGFr domains was performed using
distinct mutations rather than the prevalence of these
mutations (i.e. each mutation was included only once in
all analyses, independent of its total frequency in the
CADASIL population). Next to a comparison with the
mutation spectrum reported worldwide, we also sepa-
rately compared the spectrum of ExAC mutations to
those in the Dutch registry alone because, in contrast to
many other countries, the NOTCH3 mutation spectrum
in the Dutch population is well characterized, as
NOTCH3 mutation screening in the Netherlands is com-
prehensive for exons 2–24, has been operational for more
than 15 years and molecular diagnostics are readily acces-
sible to all Dutch citizens. Moreover, all Dutch NOTCH3
mutations are registered in a single national registry,
which includes 383 individuals with 45 distinct mutations
from 163 families. For mutation annotation, the reference
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sequence NM_000435.2 was used and sequence variants
were described according to the HGVS nomenclature rec-
ommendations.
Genotype-phenotype analysis
The confirmation of an EGFr- location-dependent geno-
type-phenotype correlation was performed in an indepen-
dent CADASIL cohort. A detailed characterization of this
cohort has been described elsewhere.10 A standardized
MRI protocol was performed at a field strength of 1.5T
(Philips Medical System). Image acquisition and volumet-
ric analysis of WMH, brain parenchyma, and lacunar
infarcts were performed as previously described.4 Briefly,
WMHs were defined as white matter areas with increased
signal intensity on T2-w MRI and FLAIR. WMH volume
was calculated as a percentage of the brain parenchyma
volume. Lacunar infarcts were defined as parenchymal
defects not extending to the cortical grey matter, with a
signal intensity corresponding to that of cerebrospinal
fluid and having a diameter between 2 mm and 1.5 cm.
Statistical analysis was performed using the SPSS statisti-
cal software package (version 23) (SPSS Inc., Chicago).
Comparison of quantitative brain MRI variables was per-
formed using linear regression, co- varying for age, sex,
smoking, and hypertension.
NOTCH3 phenotypic spectrum in over
70 year olds
As ExAC genotypes cannot be traced back to the pheno-
typic data of individuals, we could not assess the correla-
tion of genotype with (possible) CADASIL phenotype in
ExAC. To determine whether NOTCH3 mutations can be
present in asymptomatic or paucisympomatic individuals
and whether nonpenetrance may occur, we queried our
Dutch CADASIL registry for individuals of at least
70 years of age at the time of DNA-testing. We selected
only those individuals with an available brain MRI or CT
scan, determined the reason for NOTCH3 mutation test-
ing, and reviewed their clinical records and brain scans.
Results
High frequency of EGFr cysteine altering
NOTCH3 mutations in ExAC
We found a total number of 642 NOTCH3 missense vari-
ants in ExAC, of which 206 fit all the criteria for
pathogenicity in CADASIL, namely mutations leading to
an uneven number of 5 or 7 cysteine amino acids in one
of the 34 EGFr domains of the NOTCH3 protein
(Table 1). The frequency of these mutations in ExAC is
therefore 206 in 60,706 exomes, that is 3.4/1000. This is
100-fold higher than what would be expected based on
the current CADASIL prevalence estimations of 2–5/
100,000.3,18,19 In the four independently accessible ExAC
cohorts, we found the following frequencies of pathogenic
NOTCH3 mutations: Type 2 diabetes cohort
(n = 16,857): 3.9/1000; NHLBI-GO Exome Sequencing
Project (n = 6503): 1.2/1000; Sequencing Initiative Suomi
(n = 6118): 0.7/1000; 1000 Genomes (n = 2504): 3.6/
1000. This confirmation of high mutation frequencies in
all four independently accessible cohorts shows that the
high NOTCH3 mutation frequency in ExAC is not attri-
butable to a specific ExAC cohort.
Characteristics of NOTCH3 mutations in
ExAC
The 206 EGFr cysteine altering missense mutations in
ExAC consist of varying frequencies of 25 distinct muta-
tions (Table 1). Fourteen of the 25 distinct mutations are
present in ExAC only once. The other mutations are recur-
rent, and are present between two and eight times, except
for two mutations which have high frequencies of 329
and 1209. These two mutations are found across ethnici-
ties, but are most frequent in the East Asian (p.Arg544Cys)
and South Asian (p.Arg1231Cys) populations (Fig. 1). The
most frequent mutation (p.Arg1231Cys) is present in a
homozygous state in three individuals, in a population
reported to be highly consanguineous (Lek et al.; http://
dx.doi.org/10.1101/030338). The mutations are located in
10 different NOTCH3 EGFr encoding exons, encoding a
total of 12 EGFr domains. Exons 11 and 22 harbor the
most distinct mutations, namely six each, followed by
exons 4 and 12 with three distinct mutations each. Overall,
17 of the 25 mutations lead to the gain of a cysteine resi-
due in an EGFr domain and eight to the loss of a cysteine.
Comparison of NOTCH3 mutations in ExAC
to those reported in CADASIL patients
We found pathogenic NOTCH3 mutations in each of the
populations included in ExAC (Fig. 1). Mutation frequen-
cies, however, differ between the populations and range
from 0.4/1000 in African/African Americans to 11.7/1000
in South Asians. Some mutations are present in many dif-
ferent populations; the p.Arg578Cys mutation and the
p.Arg1231Cys mutation, for example, are each found in
four of six populations. Mutations found in specific eth-
nic populations in ExAC have also been reported in
CADASIL patients from the same ethnicity or geographi-
cal region. For example, the p.Arg544Cys mutation which
is very frequent in East Asians in ExAC, has also been
described frequently in CADASIL patients from Taiwan22
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and from Korea.11 Likewise, the p.Arg1231Cys mutation,
which is the most frequent mutation in Europeans in
ExAC, has also been reported in three of the large Euro-
pean CADASIL cohorts.12,13,15
Mutations in ExAC are predominantly
located outside of EGFr domains 1-6
Next, we compared the distribution of mutations in
ExAC to those in the well-characterized Dutch CADASIL
registry and to those reported in CADASIL patients
worldwide. In the Dutch CADASIL registry, there are 45
distinct cysteine altering NOTCH3 mutations, of which
six have not been previously reported (Table S1). The dis-
tribution of Dutch CADASIL-causing NOTCH3 muta-
tions largely overlaps with those reported worldwide,21
with the largest percentage of distinct mutations located
in exon 4 (Fig. 2). In ExAC, the percentage of distinct
mutations in exon 4 is three times lower than in the
Dutch CADASIL registry (12% vs. 38%). Conversely, the
percentage of distinct mutations in exon 22 is 10 times
higher in ExAC than in the Dutch CADASIL registry
(24% vs. 2%). There is a relatively high percentage of dis-
tinct mutations in exon 11 in both ExAC and the Dutch
CADASIL registry (24% and 16%, respectively). Of note,
although the distribution of mutations in ExAC differs
from the distribution found in reported CADASIL
patients, the majority of the exact same distinct EGFr cys-
teine altering NOTCH3 mutations in ExAC, namely 14
out of 25 (56%), have been previously reported in
CADASIL patients (Table 1). Finally, we compared the
mutation spectrum at the protein level using the distribu-
tion across the 34 NOTCH3 EGFr domains. This shows
that mutations in ExAC are mostly clustered in EGFr
domains 14–16 and 29–31, whereas reported CADASIL
mutations cluster in EGFr domains 1–6.
Table 1. Twenty-five distinct cysteine altering NOTCH3 mutations in the ExAC database.
cDNA Protein Exon EGFr
Count
in ExAC
Mutation previously
reported in CADASIL
c.350G>T p.Cys117Phe 4 2 1 yes32
c.619C>T p.Arg207Cys 4 5 1 yes33
c.635G>A p.Cys212Tyr 4 5 1 yes34
c.931T>G p.Cys311Gly 6 7 1 No
c.1045T>A p.Cys349Ser 7 8 1 No
c.1630C>T p.Arg544Cys 11 14 32 yes33
c.1672C>T p.Arg558Cys 11 14 5 yes12
c.1732C>T p.Arg578Cys 11 14 5 yes12
c.1759C>T p.Arg587Cys 11 15 2 yes35
c.1819C>T p.Arg607Cys 11 15 1 yes36
c.1823G>A p.Cys608Tyr 11 15 1 No
c.1871G>C p.Cys624Ser 12 16 1 No
c.1903C>T p.Arg635Cys 12 16 1 No
c.1918C>T p.Arg640Cys 12 16 3 yes [LOVD]
c.2149C>T p.Arg717Cys 14 18 3 yes [HGMD]
c.2824G>T p.Gly942Cys 18 24 1 No
c.2851C>T p.Arg951Cys 18 24 1 No
c.3427C>T p.Arg1143Cys 21 29 2 yes [HGMD]
c.3568C>T p.Arg1190Cys 22 30 5 No
c.3601C>T p.Arg1201Cys 22 30 7 No
c.3605G>C p.Cys1202Ser 22 30 1 No
c.3628C>T p.Arg1210Cys 22 31 1 yes [Netherlands]
c.3664T>G p.Cys1222Gly 22 31 8 yes3
c.3691C>T1 p.Arg1231Cys1 22 31 120 yes12
c.3724C>T p.Arg1242Cys 23 31 1 No
Total 206
Fourteen of the 25 distinct missense mutations have been previously described in CADASIL patients. The others all fit the criteria for pathogenicity
in CADASIL, namely leading to a cysteine amino acid change in one of the 34 EGFr domains of the NOTCH3 protein. Previously reported NOTCH3
mutations in CADASIL patients are shown in bold.
CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; LOVD, Leiden Open Variation Database
(www.lovd.nl/NOTCH3); HGMD, The Human Gene Mutation Database (http://www.hgmd.cf.ac.uk).
1Mutation reported three times in a homozygous state.
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NOTCH3 mutations outside of EGFr domains
1–6 are correlated with a lower MRI lesion
load
The observed difference in mutation distribution between
mutations in ExAC and those reported in CADASIL led us
to hypothesize that a genotype-phenotype correlation may
play a role. Specifically, we hypothesized that mutations
outside of EGFr domains 1–6, the classical CADASIL pre-
dominance region, predispose to a less severe phenotype.
To test this hypothesis, we compared the WMH lesion load
and number of lacunar infarcts between patients with a
mutation in EGFr domains 1–6 to patients with a mutation
in EGFr domains 7–34. We found that patients with muta-
tions in EGFr domains 1–6 had a significantly higher
WMH lesion load than patients with mutations in EGFr
domains 7–34 (Fig. 3A). A similar trend was seen for the
number of lacunar infarcts, almost reaching statistical sig-
nificance (Fig. 3B). Although group size for this analysis is
relatively small, these results suggest that mutations outside
of NOTCH3 EGFr domains 1–6 are associated with a less
severe brain MRI phenotype.
NOTCH3 mutations are penetrant on brain
imaging in paucisymptomatic elderly
individuals
To determine whether NOTCH3 mutations can be associ-
ated with nonpenetrance or an undiagnosed phenotype,
possibly explaining the high ExAC mutation frequency,
we selected individuals from the Dutch CADASIL registry
who were 70 years or older at the time of DNA-testing
and in whom a recent brain scan was available. We iden-
tified four such individuals. The reasons for DNA-testing
were either predictive testing because of the diagnosis of
CADASIL in a family member, or because of a chance
finding of WMHs on brain imaging, performed for unre-
lated signs or symptoms, such as hearing loss. The muta-
tions in these patients were in exon 10 (p.Cys531Gly)
and in exon 11 (p.Arg587Cys). None of them had a his-
tory of stroke. One patient reported mild complaints of
memory loss, the other three had no cognitive com-
plaints at all and no cognitive deficits were reported by
their partners. All individuals lived at home and were
fully independent for activities of daily living. One
Figure 1. High frequency of EGFr cysteine altering NOTCH3 mutations in all populations in the ExAC database. Frequencies range from 0.4/1000
individuals in the African/African American population to 11.7/1000 in the South Asian population, with an overall frequency of 3.4/1000.
*: Mutation previously described in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
patients; †: Mutation reported three times in a homozygous state; (): Allele counts
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patient had a history of hypertension and hyperlipidemia,
and one patient had a history of hypercholesterolemia.
Their further clinical work-up and medical history was
unremarkable. Extensive WMHs consistent with CADA-
SIL were observed on brain imaging in all four patients.
None of the patients had lacunes, which are typically
seen up to three decades earlier in patients with classical
CADASIL (Fig. 4A–C). The individuals who had an MRI
scan, made at age 78 and 58 respectively, showed sym-
metric WMHs in both and microbleeds in one (Fig. 4D–
I). These individuals illustrate that NOTCH3 mutations
can be present in clinically asymptomatic or paucisymp-
tomatic individuals over 70 years of age, who for this
reason can easily remain undiagnosed with respect to
CADASIL.
Discussion
The frequency of EGFr cysteine altering NOTCH3 muta-
tions in the public exome database ExAC is 3.4/1000. This
frequency is 100-fold higher than the current estimated
prevalence of CADASIL. Although CADASIL is classically
described as a mid-adult onset, severe stroke and demen-
tia syndrome, a later onset and milder disease course is
increasingly recognized.3 Our results suggest that this
milder phenotype, which may be indistinguishable from
signs and symptoms of sporadic geriatric cerebral small
vessel disease, is much more prevalent than recognized to
date.
There are four possible explanations for the unexpected
high frequency of NOTCH3 mutations in ExAC, namely
Figure 2. Distribution of distinct EGFr cysteine altering NOTCH3 mutations in ExAC compared to those reported in cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) patients. Schematic representation of the NOTCH3 protein with 34
epidermal growth factor-like repeat domains (EGFr) and the NOTCH3 EGFr encoding exons (exon 2–24). Exons 25–33 (and part of exon 24)
encode the transmembrane and intracellular domains of NOTCH3; these have never been found to harbor CADASIL-causing mutations. In the
Dutch CADASIL registry and in CADASIL patients worldwide, most mutations are located in exon 4, which largely accounts for the predominance
of mutations in EGFr domains 1–6. In ExAC, this predominance is not observed, as mutations are most frequent in exons 11–12 and 22,
encoding EGFr domains 14–16 and 29–31, respectively. Pink bars above the EGFr domains represent the distribution of mutations across EGFr
domains, where the height of the pink bar reflects the percentage of mutations in the respective EGFr domain. Exon colors reflect the number of
mutations in each exon: gray indicates exons without mutations; blue indicates exons with mutations. The darker the color blue of the exon, the
higher the number of distinct mutations.
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(1) the mutations in ExAC differ from those found in
CADASIL and are not pathogenic but are polymorphisms;
(2) all the individuals with a NOTCH3 mutation in ExAC
have an undiagnosed or unreported classical CADASIL;
(3) some mutations have reduced penetrance in certain
contexts, for example, in certain populations; (4) a late-
onset, mild CADASIL phenotype which is less readily
diagnosed, is much more prevalent than recognized to
date.
The limitation of this study is that no phenotypic
information is available for individuals in the ExAC data-
base and we therefore cannot definitively confirm or
reject any of these possible explanations. However, in our
opinion, it is highly unlikely that any of the 25 EGFr cys-
teine altering NOTCH3 mutations found in ExAC are
polymorphisms, as even the two most frequent mutations
in ExAC (p.Arg544Cys and p.Arg1231Cys) have been
reported in multiple CADASIL pedigrees.12,22,23 Further-
more, more than half of the 25 mutations in ExAC have
been previously reported in CADASIL pedigrees and all
25 obey the criteria used by DNA-diagnostic laboratories
to establish pathogenicity of a NOTCH3 mutation. It
should also be noted that novel EGFr cysteine altering
NOTCH3 mutations are reported in newly diagnosed
CADASIL patients at a steady rate, with well over 200
such mutations reported to date.21
As ExAC consists of various disease and control
cohorts and does not contain any stroke or dementia
cohorts, it is unlikely that the 206 individuals with a
NOTCH3 mutation in ExAC all have an undiagnosed
classical mid-adult onset CADASIL phenotype. Nonpene-
trance in these individuals cannot be excluded but is also
unlikely, as this has never been reported for this highly
specific type of NOTCH3 mutation and we did not find
nonpenetrance in asymptomatic or paucisymptomatic
elderly individuals with a NOTCH3 mutation in our
Dutch registry. Therefore, in our opinion, the most likely
explanation for the observed high mutation frequency in
ExAC is a much higher prevalence than recognized to
date of a very mild, late-onset NOTCH3 mutation-asso-
ciated cerebral small vessel disease, which may remain
undiagnosed into old age.24
Our finding that the EGFr distribution of mutations in
ExAC differs from that found in diagnosed CADASIL
patients, suggested a possible genotype-phenotype correla-
tion. We hypothesized that mutations located in EGFr
domains 1–6 predispose to “classical” CADASIL and, con-
versely, mutations outside of EGFr domains 1–6 predispose
to a much milder phenotype. This would also explain why
most CADASIL patients diagnosed to date have a mutation
in exon 4, as these have a more severe phenotype and are
therefore much more readily diagnosed. We confirmed our
hypothesis in a well-characterized independent Dutch
CADASIL cohort,7 in which we found that patients with a
mutation in EGFr domains 1–6 have a significantly higher
MRI lesion load than those with mutations in EGFr
domains 7–34. Interestingly, the paucisymptomatic elderly
individuals in our Dutch cohort all had a mutation outside
of EGFr domains 1–6, which is also the case in other mildly
affected CADASIL patients reported in the literature.24,25
We can only speculate as to why mutations in certain EGFr
domains may have more detrimental effects than others.
Possibly, an unpaired cysteine in EGFr domains 1–6, at the
N-terminus of the NOTCH3 extracellular domain, more
readily interacts with other proteins, leading to a stronger
effect on CADASIL-associated protein multimeriza-
tion.26,27 Although this novel genotype-phenotype correla-
tion may help predict a predisposition to a milder or a
Figure 3. Correlation between EGFr location of the NOTCH3
mutation and MRI lesion load in cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencephalopathy
(CADASIL) patients. MRI quantification data from patients with a
mutation in EGFr domains 1–6 (n = 32) compared to patients with a
mutation in EGFr domains 7–34 (n = 8). (A) White matter
hyperintensity volume (expressed as the % of total brain parenchymal
volume), was significantly higher in patients with mutations in EGFr
domains 1–6 than in patients with mutations in EGFr domains 7–34
(8.0% vs. 4.3%, P = 0.01). (B) The number of lacunar infarcts
showed a similar trend (14.5 vs. 4.8, P = 0.05). Bars represent mean
 SEM, corrected for age, sex, smoking and hypertension.
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more severe CADASIL phenotype, this needs further delin-
eating in larger cohorts before it can be used in the clinical
setting. Also, clearly, factors other than NOTCH3 genotype
play an important role in CADASIL. For example, smoking
and hypertension have been shown to be associated with
CADASIL disease severity.13
A worldwide prevalence of pathogenic NOTCH3 muta-
tions of 3.4/1000 individuals implies that these mutations
may be a major contributor to cerebral small vessel dis-
ease in the general population. Indeed, a recent study in
patients with adult-onset leukoencephalopathy showed
that 21% of these individuals had a pathogenic NOTCH3
mutation.28 Similarly, high NOTCH3 mutation frequen-
cies (18%) were found in a Korean cohort of patients
with subcortical vascular cognitive impairment.29 Con-
versely, in a cohort of individuals with confluent white
matter lesions or lacunes, no cysteine altering NOTCH3
mutations were found.30 Future studies in large, well-
characterized cohorts are needed to determine the role of
cysteine altering NOTCH3 mutations in the development
of white matter hyperintensities and vascular cognitive
impairment in the general population.
Our study illustrates how large whole exome datasets
can alter mutation-disease paradigms. This was recently
Figure 4. Brain MRI of elderly asymptomatic and paucisymptomatic individuals with a NOTCH3 mutation compared to MRI in classical cerebral
autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). (A–C) Brain MRI images of a classical CADASIL
phenotype in the 6th decade. (A–B) FLAIR images showing extensive confluent symmetric white matter hyperintensities and multiple lacunar
infarcts (arrows indicate random samples). (C) T2*-weighted MRI showing multiple microbleeds (open arrows indicate random samples). (D–F)
Brain MRI images of a female, diagnosed with CADASIL after predictive DNA testing at 78 years of age, with only very mild clinical symptoms. (D,
E) FLAIR images showing symmetric white matter hyperintensities, but no lacunar infarcts. (F) T2*- weighted MRI showing some small
microbleeds (open arrows). (G-I) Dual echo images of a female who was still clinically asymptomatic at 73 years of age. MRI images were made
at 58 years of age, showing very mild symmetric white matter hyperintensities, no lacunar infarcts and no microbleeds.
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also illustrated by a study reporting an unexpected high
frequency of prion disease- associated PRNP mutations in
ExAC.31 Although our finding of high NOTCH3 mutation
frequencies shows some similarities to this study, there
are also fundamental differences between NOTCH3 muta-
tions in CADASIL and PRNP mutations in prion disease.
The most important difference is the fact that many dif-
ferent types of PRNP variants have been described, with
variable levels of evidence for pathogenicity. This is in
sharp contrast to the highly stereotyped nature of patho-
genic NOTCH3 mutations in CADASIL.
In conclusion, we show that the frequency of EGFr cys-
teine altering NOTCH3 mutations in a large exome data-
set is 3.4/1000 and we discovered the first genotype-
phenotype correlation in CADASIL, which is related to
the distribution of mutations across NOTCH3 EGFr
domains. These findings fundamentally change the
CADASIL disease paradigm and cause us to redefine the
phenotypic spectrum associated with EGFr cysteine alter-
ing NOTCH3 mutations.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Table S1. Pathogenic NOTCH3 mutations in the Nether-
lands. Between 1998 and 2014, 45 distinct mutations have
been detected in the Netherlands. Six mutations are espe-
cially prevalent (shown in bold), these include both
(Dutch) founder mutations and recurrent mutations
(Unpublished). *mutations which have not been previ-
ously reported, †mutation reported two times in a
homozygous state.
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